Moody Aldrich Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Moody Aldrich Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.07M	Sell	90,617 -24,358	-21%	-$803K	0.55%	88
2026 Q1	$3.68M	Sell	114,975 -28,574	-20%	-$931K	0.66%	72
2025 Q4	$5.04M	Buy	+143,549	New	+$5.22M	0.94%	34
2025 Q1	–	Sell	-79,145	Closed	-$2.03M	–	203
2024 Q4	$2.03M	Sell	79,145 -137,348	-63%	-$2.92M	0.38%	93
2024 Q3	$3.59M	Sell	216,493 -4,174	-2%	-$72.2K	0.65%	70
2024 Q2	$4.24M	Buy	220,667 +109,400	+98%	+$2.19M	0.83%	57
2024 Q1	$2.63M	Buy	+111,267	New	+$2.26M	0.45%	83

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Moody Aldrich Partners's NAMS Position: Q2 2026 in Review

Moody Aldrich Partners reduced its NewAmsterdam Pharma (NAMS) stake by 21% in Q2 2026, selling an estimated $803K and leaving 90,617 shares worth $3.07M. The position accounts for 0.55% of the portfolio, ranked #88.

Moody Aldrich Partners first reported a position in NAMS in Q1 2024 and has held it in 7 quarters since. The position peaked at $5.04M in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Moody Aldrich Partners held 90,617 shares of NewAmsterdam Pharma worth $3.07M as of Q2 2026.
Moody Aldrich Partners sold 24,358 NewAmsterdam Pharma shares in Q2 2026, an estimated $803K.
NewAmsterdam Pharma made up 0.55% of Moody Aldrich Partners's portfolio in Q2 2026, its #88 holding.
Moody Aldrich Partners first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 7 quarters since.
Moody Aldrich Partners's NewAmsterdam Pharma position peaked at $5.04M in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.